Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BGB-43395 in Advanced or Metastatic HR+/HER2- Breast Cancer and Other Solid Tumors
NCT06253195Phase 1Completed
- Sponsor
- BeOne Medicines
- Start
- Apr 2024
- Primary completion
- Apr 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of bgb-43395 in breast cancer and solid tumor (2 arms), sponsored by BeOne Medicines. Primary endpoints: Number of Participants with Adverse Events and Serious Adverse Events at 30 months, Maximum Tolerated Dose or Maximum Administered Dose of BGB-43395 at 30 months and 2 more. Started Apr 2024; status: completed.
02
Drugs
bgb-43395
03
Conditions
breast cancersolid tumor
Beyond the preview
Go deeper on NCT06253195.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06253195.